Up-to-date List of Keppra Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Keppra Medical Research Studies

1 Unknown  Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia
Condition: Epilepsy & Cognitively Impaired Elderly
Intervention: Drug: Levetiracetam
Outcome Measures: The primary measures of interest are the cognitive and mini-mental state exam scores, number of seizure episodes assessed across time. In addition, several ratings such as activities of daily living, behavior and motor activity will also be evaluated.;   Several ratings such as activities of daily living, behavior and motor activity will also be evaluated.
2 Recruiting Comparison of Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After Subarachnoid Hemorrhage (SAH)
Condition: Subarachnoid Hemorrhage
Interventions: Drug: Levetiracetam short course;   Drug: Levetiracetam Long course
Outcome Measures: In-hospital seizures after SAH;   Compare incidence of seizure after hospital discharge and/or development of epilepsy;   Compare incidence of adverse drug reactions related to levetiracetam and the rate of discontinuation of medication secondary to the reaction;   Compare intensive care and hospital length of stay between regimens;   Evaluate differences in cognitive and functional outcomes at discharge and outpatient follow-up
3 Recruiting Efficacy of Intravenous Levetiracetam in Neonatal Seizures
Condition: Neonatal Seizures
Interventions: Drug: Intravenous levetiracetam;   Drug: Intravenous phenobarbital
Outcome Measures: To determine the efficacy of intravenous LEV in terminating neonatal seizures when given as first line therapy compared to phenobarbital;   To obtain dose escalation data by studying the additional efficacy of a further dose in non responders.;   To evaluate the benefit of remote EEG monitoring;   Evaluation of the accuracy of neonatal seizure detection algorithm
4 Not yet recruiting Levetiracetam for Alzheimer's Disease-Associated Epileptiform Activity
Condition: Early-onset Alzheimer's Disease
Intervention: Drug: levetiracetam
Outcome Measures: Changes in Epileptiform Activity Frequency;   Changes in Cognitive Function as Measured by a Virtual Navigation Task;   Changes in Cognitive Function as Measured by a Standard Neuropsychological Assessment;   Changes in Executive Function as Measured by the E.X.A.M.I.N.E.R. Computer Battery
5 Not yet recruiting Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study
Conditions: Subarachnoid Hemorrhage;   Seizures
Intervention: Drug: levetiracetam
Outcome Measures: Randomization Yield;   Protocol Adherence Yield
6 Recruiting Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures
Conditions: Epilepsy;   Partial Seizures
Interventions: Drug: Levetiracetam;   Drug: Carbamazepine
Outcome Measures: Proportion of subjects remaining seizure free during the 6-months Evaluation Period;   Proportion of subjects retained in the study for the duration of the period covering the Up Titration Period, Stabilization Period, and Evaluation Period;   Time to first seizure or discontinuation due to an Adverse Event (AE) / Lack of Efficacy (LOE) during the Evaluation Period;   Time to first seizure during the Evaluation Period;   Time to first seizure during the period covering the Up Titration Period, Stabilization Period, and Evaluation Period from the first dose of study drug
7 Recruiting Cognitive Effects of Treatment of Interictal Discharges
Condition: Epilepsy
Interventions: Drug: levetiracetam;   Drug: Lamotrigine
Outcome Measures: Reduction of focal interictal discharges. The proposed study tests the hypothesis that treatment with levetiracetam will reduce focal interictal epileptiform activity.;   Reduction of generalized interictal discharges. The proposed study tests the hypothesis that treatment with lamotrigine will reduce generalized interictal epileptiform activity.;   The study will evaluate the hypothesis that reduction of focal and generalized interictal epileptiform activity is associated with improved performance on neuropsychological batteries and computerized cognitive testing.
8 Unknown  Levetiracetam in the Management of Bipolar Depression
Condition: Bipolar Depression
Interventions: Drug: Levetiracetam;   Drug: Placebo
Outcome Measures: Change in depressive symptom scores from baseline.;   Number of subjects who achieve remission.;   Change in ratings on the Clinical Global Impressions Scale for Bipolar Disorder (CGI-BP).
9 Unknown  Effects of Keppra on Thinking, Emotions, and Balance in Elderly Healthy Volunteers
Condition: Epilepsy
Intervention: Drug: Levetiracetam (Keppra)
Outcome Measures: 1.Objective Neuropsyhological testing;   2.Subjective Behavioral Measures;   3.Balance Measures
10 Unknown  Levetiracetam Versus Carbamazepine in Post-Stroke Late Onset Crisis
Conditions: Epileptic Seizures;   Stroke
Interventions: Drug: Levetiracetam;   Drug: Carbamazepine
Outcome Measures: number of patients free from post stroke recurrent crisis;   To compare retention time of LEV vs CBZ since first intake throughout treatment period;   To compare time to second seizure in both treatments.;   To evaluate differences in cognitive function and in quality of life in levetiracetam and carbamazepine patients having post-stroke seizures at the end of treatment period;   evaluate EEG changes as compared with baseline with that obtained at the end of treatment period;   To compare seizure frequency in levetiracetam and carbamazepine groups throughout treatment period;   To evaluate the safety of levetiracetam versus carbamazepine throughout the treatment period
11 Recruiting Evaluate Retention Rate of Topiramate, Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment
Condition: Epilepsy
Outcome Measures: Retention rate of topiramate, levetiracetam and oxcarbazepine during 24 months of treatment;   Evaluate the confounding factors affecting the retention rate;   Evaluate the response rate through seizure reduction (≥75%, ≥50%) in 2-year treatment with each antiepileptic drugs (topiramate, levetiracetam, oxcarbazepine)
12 Unknown  Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus
Condition: Status Epilepticus
Intervention: Drug: levetiracetam (add-on)
Outcome Measures: o Uneventful intravenous (iv) administration of study medication;   o Toxicity profile on iv administration, including:;   § Irritation on injection site;   § Hypotension, defined as systolic blood pressure below 90 mm Hg recorded within 24 hours of the dose;   § Cardiac arrest (diagnosed clinically) or bradyarrhythmias including heart block, documented on an electrocardiogram;   § Respiratory depression, defined as the occurrence of apnea or need for intubation;   § Allergic reactions, like skin rash;   § Other side-effects;   Pharmacokinetic parameters of levetiracetam and clonazepam in patients with SE
13 Unknown  Efficacy of Keppra in Acute Alcohol Related Seizure Control--A Pilot Study
Condition: Seizure, Alcohol Related
Intervention: Drug: levetiracetam
Outcome Measure: Decreased seizures
14 Unknown  Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization
Conditions: Epilepsy;   Partial Seizures
Interventions: Drug: Levetiracetam;   Drug: Placebo
Outcome Measures: Partial onset seizure frequency per week.;   Safety descriptive about occurence of adverse events, evaluation of results of clinical/physical examination and ECG and laboratory tests results.;   Proportions of response between the groups of treatment. (Responders defined as number of patients with at least 50% reduction in the number of weekly partial seizures);   Percentage reduction from baseline in partial seizure frequency of days a week.;   Proportion of response between the groups of treatment. (Responders defined as number of subjects with at least 50% reduction in the number of days per week with partial seizures);   Proportion between the groups of treatment without any kind of seizures. (seizure free)
15 Recruiting Seizure Activity in Alzheimer's Disease
Conditions: Alzheimer's Disease;   Seizures
Intervention: Drug: Low/High/Placebo Dose Keppra (Levetiracetam)
Outcome Measures: Brain Perfusion Blood Flow fMRI;   Free and Cued Selective Reminding Test;   Mini Mental Status Exam (MMSE);   Trial Making Test Parts A & B;   Phonemic & Category Fluency Test;   Boston Naming Test 15-item version
16 Not yet recruiting A Study to Compare the Effectiveness of Three Drugs, Fosphenytoin, Levetiracetam and Valproic Acid in Terminating Prolonged Seizures (Status Epilepticus) That do Not Respond to Benzodiazepines.
Condition: Status Epilepticus ( Prolonged Seizures) Not Responding to Benzodiazepines
Interventions: Drug: Fosphenytoin;   Drug: Levetiracetam;   Drug: Valproic acid
Outcome Measures: Clinical cessation of SE without life threatening hypotension or cardiac arrhythmias.;   Admission to ICU, intubation and mortality
17 Recruiting Seizure Prophylaxis in Aneurysm Repair
Conditions: Intracranial Aneurysms;   Seizure
Intervention: Drug: Levetiracetam
Outcome Measure: Incidence of seizure
18 Unknown  Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy
Conditions: Epilepsy;   Glioma
Outcome Measures: to correlate the efficacy of post-operative levetiracetam monotherapy in newly diagnosed glioma patients suffering from epilepsy with expression of synaptic vesicle protein 2A (SV2A).;   to determine the impact of levetiracetam monotherapy on neurocognitive functioning, health-related quality of life, and epileptic brain activity as measured by MEG, in newly diagnosed glioma patients with epilepsy
19 Recruiting A Dose-Escalation, Safety and Feasibility Study of Enteral Levetiracetam for Seizure Control in Pediatric Cerebral Malaria
Conditions: Seizure;   Epilepsy;   Cerebral Malaria
Interventions: Drug: Oral Levetiracetam;   Drug: Standard AED
Outcome Measures: Minutes with seizure on EEG;   The AEDs required during admission;   Mean time from admission to BCS >/= 4;   Sequelae
20 Recruiting Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Conditions: Epilepsy, Partial;   Epilepsy, Localization Related;   Adverse Effects
Interventions: Drug: Oxcarbazepine;   Drug: levetiracetam;   Drug: lamotrigine
Outcome Measures: Conners' Continuous Performance Test (CPT) Confidence Interval;   Child Behavior Checklist

These studies may lead to new treatments and are adding insight into Keppra etiology and treatment.

A major focus of Keppra research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Keppra

© Copyright 2019.

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly. PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.

Privacy | Terms | Contact us

privacy policy